אנסטרוז ישראל - עברית - Ministry of Health

אנסטרוז

taro international ltd - anastrozole 1 mg - tablets - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.

פרוגרף 1 מג ישראל - עברית - Ministry of Health

פרוגרף 1 מג

astellas pharma international b.v., israel - tacrolimus - קפסולות - tacrolimus 1 mg - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients.treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.

פרוגרף 1 מג ישראל - עברית - Ministry of Health

פרוגרף 1 מג

astellas pharma international b.v., israel - tacrolimus - קפסולות - tacrolimus 1 mg - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients.treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.

פרוגרף 5 מג ישראל - עברית - Ministry of Health

פרוגרף 5 מג

astellas pharma international b.v., israel - tacrolimus - קפסולות - tacrolimus 5 mg - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients. treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.

פרוגרף 5 מג ישראל - עברית - Ministry of Health

פרוגרף 5 מג

astellas pharma international b.v., israel - tacrolimus - קפסולות - tacrolimus 5 mg - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients. treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.

פרוגרף אמפולות ישראל - עברית - Ministry of Health

פרוגרף אמפולות

astellas pharma international b.v., israel - tacrolimus - תרכיז להכנת תמיסה לאינפוזיה - tacrolimus 5 mg/ml - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients.treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.

פרוגרף 0.5 מג ישראל - עברית - Ministry of Health

פרוגרף 0.5 מג

astellas pharma international b.v., israel - tacrolimus - קפסולות - tacrolimus 0.5 mg - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients. treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.

פרוגרף 0.5 מג ישראל - עברית - Ministry of Health

פרוגרף 0.5 מג

astellas pharma international b.v., israel - tacrolimus - קפסולות - tacrolimus 0.5 mg - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients. treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.

ברקסין טבליות ישראל - עברית - Ministry of Health

ברקסין טבליות

taro international ltd, israel - piroxicam as beta-cyclodextrin - טבליה - piroxicam as beta-cyclodextrin 20 mg - piroxicam - piroxicam - piroxicam is indicated for symptomatic relief of osteoarthritis rheumatoid arthritis or ankylosing spondylitis. when an nsaid is indicated piroxicam should be considered as a second line option. the desicion to prescribe piroxocam should be based on an assesment of the individual's patient overall risk.

ברקסין שקיות ישראל - עברית - Ministry of Health

ברקסין שקיות

taro international ltd, israel - piroxicam as beta-cyclodextrin - אבקה מסיסה במים - piroxicam as beta-cyclodextrin 20 mg - piroxicam - piroxicam - piroxicam is indicated for symptomatic relief of osteoarthritis rheumatoid arthritis or ankylosing spondylitis. when an nsaid is indicated piroxicam should be considered as a second line option. the desicion to prescribe piroxocam should be based on an assesment of the individual's patient overall risk